Incyte (INCY)
(Delayed Data from NSDQ)
$51.65 USD
-0.73 (-1.39%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $51.63 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Incyte (INCY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$75.78 | $93.00 | $60.00 | 45.96% |
Price Target
Based on short-term price targets offered by 18 analysts, the average price target for Incyte comes to $75.78. The forecasts range from a low of $60.00 to a high of $93.00. The average price target represents an increase of 45.96% from the last closing price of $51.92.
Analyst Price Targets (18)
Broker Rating
Incyte currently has an average brokerage recommendation (ABR) of 2.05 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 19 brokerage firms. The current ABR compares to an ABR of 2.05 a month ago based on 19 recommendations.
Of the 19 recommendations deriving the current ABR, nine are Strong Buy, representing 47.37% of all recommendations. A month ago, Strong Buy represented 47.37%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 10 | 10 | 10 | 10 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.05 | 2.05 | 2.05 | 2.05 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/14/2024 | BMO Capital Markets | Evan Seigerman | Hold | Hold |
2/14/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
2/14/2024 | JMP Securities | Reni Benjamin | Strong Buy | Hold |
2/6/2024 | William Blair | Matt Phipps | Strong Buy | Strong Buy |
12/13/2023 | SVB Securities | Andrew Berens | Hold | Strong Buy |
12/4/2023 | Guggenheim Securities | Michael Schmidt | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.05 |
ABR (Last week) | 2.05 |
# of Recs in ABR | 19 |
Average Target Price | $75.78 |
LT Growth Rate | 11.20% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 77 of 252 |
Current Quarter EPS Est: | 0.87 |